Although several in vitro approaches were successful in separating chemicals as skin sensitizers and non-sensitizers, none of the available methods completely mimics the absolute in vivo scenario of skin sensitization. One of the major challenges with currently available systems would be the limited or no metabolic capacity to activate pre- or pro-haptens to reactive metabolites in the system. In the present study, E. coli cells with β-galactosidase-expressing LacZ gene were combined with either induced rat liver S-9 fractions or microsomal fractions to detect pre- or pro-haptens to cause skin sensitization. Following optimization of some experimental conditions, we examined 20 sensitizers classified as pre- or pro-haptens and 11 non-sensitizers in these E. coli cultures by incubating bacterial cells and test chemicals with and without S-9 or microsomal proteins. After a 6-h incubation in the presence of IPTG, cells were lyzed to determine the suppression of β-galactosidase enzyme. A cut-off of 17.3% was applied to determine the percent suppression of β-galactosidase activity by test chemicals to classify skin sensitizers and non-sensitizers. Among chemicals tested, 19 pre- or pro-haptens were categorized as true positives and 8 non-sensitizers were categorized as true negatives. Thereby, the overall sensitivity, specificity and accuracy achieved with microsome-incorporated and S-9 fraction-incorporated group were 95.0%, 72.7% and 87.1% and 80.0%, 81.8% and 80.6%, respectively. The results suggested that the present bacterial system incorporated with the microsomal activation system could be considered as a useful alternative method to classify not only direct-acting sensitizers but also pre- or pro-haptens requiring metabolic activation in vitro.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2019.01.015DOI Listing

Publication Analysis

Top Keywords

pre- pro-haptens
24
skin sensitization
12
skin sensitizers
8
sensitizers non-sensitizers
8
test chemicals
8
suppression β-galactosidase
8
categorized true
8
pro-haptens
6
skin
5
pre-
5

Similar Publications

The inter-laboratory validation study of EpiSensA for predicting skin sensitization potential.

J Appl Toxicol

April 2024

Japanese Center for the Validation of Alternative Methods (JaCVAM), National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kanagawa, 210-9501, Japan.

The Epidermal Sensitization Assay (EpiSensA) is a reconstructed human epidermis (RhE)-based gene expression assay for predicting the skin sensitization potential of chemicals. Since the RhE model is covered by a stratified stratum corneum, various kinds of test chemicals, including lipophilic ones and pre-/pro-haptens, can be tested with a route of exposure akin to an in vivo assay and human exposure. This article presents the results of a formally managed validation study of the EpiSensA that was carried out by three participating laboratories.

View Article and Find Full Text PDF

Background: Chemical-induced allergies at workplace represent a significant occupational health issue. These substances must be properly identified as sensitizers. In previous studies, an original model using mouse bone marrow-derived dendritic cells (BMDC) was developed for this purpose.

View Article and Find Full Text PDF

The hazards and potency of skin sensitizers are traditionally determined using animal tests such as the local lymph node assay (LLNA); however, significant progress has been made in the development of non-animal test methods addressing the first three mechanistic key events of adverse outcome pathway in skin sensitization. We developed the epidermal sensitization assay (EpiSensA), which is a reconstructed human epidermis-based assay, by measuring four genes related to critical keratinocyte responses during skin sensitization. Four in vitro skin sensitization test methods (EpiSensA, direct peptide reactivity assay [DPRA], KeratinoSens™, and human cell line activation test [h-CLAT]) were systematically evaluated using 136 chemicals including lipophilic chemicals and pre/pro-haptens, which may be related to assay-specific limitations.

View Article and Find Full Text PDF

Consumer products containing botanicals or natural substances (BNS) are often preferred because there is a perception that 'natural' is safe. As with any product ingredient, a thorough safety assessment must be conducted, including a determination of skin sensitization potential. A modification of the Peroxidase Peptide Reactivity Assay (PPRA) was explored for screening BNS (B-PPRA) for their reactivity to a model cysteine peptide.

View Article and Find Full Text PDF

Considerable progress has been made in the design of New Approach Methodologies (NAMs) for the hazard identification of skin sensitising chemicals. However, effective risk assessment requires accurate measurement of sensitising potency, and this has proven more difficult to achieve without recourse to animal tests. One important requirement for the development and adoption of novel approaches for this purpose is the availability of reliable databases for determining the accuracy with which sensitising potency can be predicted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!